Investor Presentaiton

Other Markets Emerging markets Developed LUPIN EU5 Australia South Africa . Germany: EUR 7.4 mn sales in Q1 FY22 UK: gFostair launch preparations on track 4th largest generics player¹ Acquisition of Southern Cross Pharma to significantly increase value proposition and market share in the Australian market 5th largest Rx generics player²; Market leader in CVS space ZAR 273 mn sales in Q1 FY22 (up 15% YoY) Brazil Mexico API + Global Institutional • • BRL 63 mn sales in Q1 FY22 (up 15% YoY) Outperformed market growth across the OTC segment MXN 163 mn sales in Q1 FY22; (growth of 33% YoY) Market Leader in Ophthalmology (#2 in units) with a national footprint API revenues down 3.8% QoQ on lower offtake of anti-infectives Received Tentative U.S.FDA Approval for Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (TLD) Tablets under PEPFAR Note: 1. IQVIA Mar-21 2. IQVIA May-21 09

View entire presentation